Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the expressions of vascular endothelial growth factor-C (VEGF-C), C-erbB-2, p53, estrogen receptor (ER), and progesterone receptor (PR) in breast cancer tissue and their clinical significance.
Methods: The expressions of C-erbB-2, p53, ER, and PR in 60 breast cancer tissues were detected using immunohistochemistry, and their clinical significance was analyzed.
Results: The positivity rates of VEGF-C, C-erbB-2, p53, ER, and PR in the 60 breast cancer tissues were 56.7%, 38.3%, 46.7%, 48.3% and 53.3%, respectively. The expressions of VEGF-C and C-erbB-2 differed significantly in relation to the lymph node status (P<0.05), but not to the patient's age or tumor volume (P>0.05). The expression of VEGF-C was positively correlated to that of C-erbB-2 (P<0.05). The expression of p53 was positively correlated to the tumor volume (P<0.05). The expressions of ER and PR were not correlated to the patient's age, tumor volume and lymph node status (P>0.05), but were inversely correlated to C-erbB-2 expression (P<0.05) independent of VEGF-C and p53 expressions (P>0.05).
Conclusions: The high expressions of VEGF-C and C-erbB-2 are closely related to lymph node metastasis in breast cancer patients, and may cooperate in promoting lymph node metastasis of breast carcinoma. Combined detection of VEGF-C, C-erbB-2, p53, ER and PR may help clinical treatment and prognostic evaluation of breast cancer patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hormone Receptor-Dependent Correlations Between Angiopoietins and VEGF-C in Primary Breast Cancer: Insights Into Lymphangiogenic Biomarkers.
Cancer Rep (Hoboken)
May 2025
Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Biomarkers of angiogenesis and lymphangiogenesis have been explored in cancer prognostic models; however, their potential role in assessing local tumor invasiveness remains poorly understood.
Aims: This study aimed to evaluate the correlations of angiogenic biomarkers, specifically the angiopoietin (ANG)-Tie system and vascular endothelial growth factor-C (VEGF-C), with lymphangiogenesis and the related histopathological characteristics in Iranian women with breast cancer.
Methods And Results: In this consecutive case series (n = 149) from the Breast Cancer Risk and Lifestyle (BCRL) study, plasma levels of pro-angiogenic factors, including VEGF-C, ANGs, and Tie-2, were assessed using ELISA.
Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Clin Breast Cancer
April 2020
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Introduction: Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy.
Patients And Methods: We retrieved publicly available complementary DNA microarray data from 399 human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer samples from patients who underwent standard neoadjuvant chemotherapy.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Gynecol Obstet Invest
June 2018
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Background: Undifferentiated endometrial sarcoma (UES) is a very rare subtype of uterine sarcoma, which has no consensus on the treatment. We investigated the expression of potential new therapeutic targets in UES to improve its aggressive clinical course and poor survival outcome.
Methods: The immunohistochemical expressions of vascular endothelial growth factor (VEGF), c-KIT, c-ABL, platelet derived growth factor receptor (PDGFR), protein kinase B (AKT1), mammalian target of rapamycin, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER2), Wilms tumor (WT1), aromatase inhibitor (CYP19A1), and histone deacetylase (HDAC) series in 10 UES patients were assessed using tissue microarrays.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Br J Cancer
October 2016
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, Texas 77030, USA.
Background: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D, and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma.
View Article and Find Full Text PDFOver-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
PLoS One
May 2016
The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China; Cancer Research Center of Shantou University Medical College, Shantou, Guangdong, China; Changjiang Scholar's Research Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guan
Overexpression of Twist, a highly conserved basic helix-loop-helix transcription factor, is associated with epithelial-mesenchymal transition (EMT) and predicts poor prognosis in various kinds of cancers, including breast cancer. In order to further clarify Twist's role in breast cancer, we detected Twist expression in breast cancer tissues by immunohistochemistry. Twist expression was observed in 54% (220/408) of breast cancer patients and was positively associated with tumor size, Ki67, VEGF-C and HER2 expression.
View Article and Find Full Text PDF